151.43
price down icon2.84%   -4.43
pre-market  Pre-mercato:  151.43  
loading
Precedente Chiudi:
$155.86
Aprire:
$156.73
Volume 24 ore:
575.19K
Relative Volume:
1.36
Capitalizzazione di mercato:
$9.10B
Reddito:
$354.82M
Utile/perdita netta:
$-462.76M
Rapporto P/E:
-18.68
EPS:
-8.105
Flusso di cassa netto:
$-460.07M
1 W Prestazione:
-5.97%
1M Prestazione:
-3.29%
6M Prestazione:
+3.29%
1 anno Prestazione:
-0.36%
Intervallo 1D:
Value
$148.40
$158.45
Intervallo di 1 settimana:
Value
$143.81
$161.91
Portata 52W:
Value
$111.09
$169.37

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
Nome
Ascendis Pharma A S Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
1,017
Name
Cinguettio
Name
Prossima data di guadagno
2024-12-13
Name
Ultimi documenti SEC
Name
ASND's Discussions on Twitter

Confronta ASND con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ASND
Ascendis Pharma A S Adr
151.43 9.10B 354.82M -462.76M -460.07M -8.105
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.74 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
617.00 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
567.09 34.59B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
255.76 33.10B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
271.04 29.15B 3.81B -644.79M -669.77M -6.24

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-07 Iniziato UBS Buy
2024-09-05 Aggiornamento Oppenheimer Perform → Outperform
2024-06-25 Aggiornamento TD Cowen Hold → Buy
2024-05-31 Iniziato Stifel Buy
2023-12-20 Iniziato Jefferies Buy
2023-06-14 Ripresa Credit Suisse Neutral
2023-04-05 Downgrade Oppenheimer Outperform → Perform
2023-04-04 Downgrade Morgan Stanley Overweight → Equal-Weight
2023-04-03 Downgrade Credit Suisse Outperform → Neutral
2022-10-20 Iniziato Goldman Buy
2022-08-30 Ripresa Berenberg Buy
2022-03-28 Ripresa Wedbush Outperform
2022-03-15 Aggiornamento BofA Securities Neutral → Buy
2022-03-01 Iniziato Citigroup Buy
2022-02-14 Aggiornamento Oppenheimer Perform → Outperform
2022-01-06 Iniziato Cowen Market Perform
2021-12-08 Iniziato Wells Fargo Overweight
2021-10-20 Downgrade BofA Securities Buy → Neutral
2021-03-30 Downgrade Oppenheimer Outperform → Perform
2021-03-11 Ripresa Stifel Buy
2020-12-17 Iniziato Berenberg Buy
2020-09-14 Ripresa JP Morgan Overweight
2020-03-20 Iniziato Oppenheimer Outperform
2019-10-11 Iniziato Morgan Stanley Overweight
2019-03-25 Iniziato Evercore ISI Outperform
2019-01-24 Iniziato Cantor Fitzgerald Overweight
2019-01-24 Aggiornamento Leerink Partners Mkt Perform → Outperform
2018-06-26 Iniziato Stifel Buy
2018-04-02 Reiterato Leerink Partners Mkt Perform
2017-05-11 Iniziato JP Morgan Overweight
2017-03-09 Downgrade Leerink Partners Outperform → Mkt Perform
2017-02-09 Iniziato Credit Suisse Outperform
2016-09-26 Iniziato Wedbush Outperform
Mostra tutto

Ascendis Pharma A S Adr Borsa (ASND) Ultime notizie

pulisher
Mar 19, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView

Mar 19, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 18, 2025

Autohome ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Inkl

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView

Mar 12, 2025
pulisher
Mar 09, 2025

Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com

Mar 06, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025
pulisher
Feb 20, 2025

Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga

Feb 20, 2025
pulisher
Feb 20, 2025

Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl

Feb 20, 2025
pulisher
Feb 19, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 18, 2025

Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl

Feb 18, 2025
pulisher
Feb 17, 2025

Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com

Feb 17, 2025
pulisher
Feb 13, 2025

ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News

Feb 13, 2025
pulisher
Feb 12, 2025

Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

Ascendis Pharma launches $25 million share buyback - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView

Feb 12, 2025
pulisher
Feb 11, 2025

Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Cantor Fitzgerald maintains Ascendis Pharma Overweight rating - Investing.com

Feb 11, 2025
pulisher
Feb 03, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN

Feb 03, 2025
pulisher
Jan 29, 2025

JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com

Jan 29, 2025
pulisher
Jan 29, 2025

Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World

Jan 29, 2025
pulisher
Jan 15, 2025

Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com

Jan 15, 2025
pulisher
Jan 13, 2025

BioMarin sues Ascendis Pharma over patent infringement - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com

Jan 13, 2025
pulisher
Jan 12, 2025

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN

Jan 12, 2025
pulisher
Jan 07, 2025

European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN

Jan 07, 2025
pulisher
Jan 07, 2025

UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com

Jan 07, 2025
pulisher
Dec 31, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN

Dec 31, 2024
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN

Dec 29, 2024
pulisher
Dec 20, 2024

Ascendis Pharma's SWOT analysis: stock poised for growth amid challenges - Investing.com

Dec 20, 2024
pulisher
Dec 18, 2024

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN

Dec 18, 2024
pulisher
Dec 16, 2024

Ascendis Pharma target raised to $194 on positive trial results - Investing.com

Dec 16, 2024
pulisher
Dec 07, 2024

European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN

Dec 07, 2024
pulisher
Nov 21, 2024

Ascendis Pharma's SWOT analysis: stock faces growth hurdles amid pipeline promise - Investing.com

Nov 21, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN

Nov 20, 2024
pulisher
Oct 21, 2024

TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com

Oct 21, 2024
pulisher
Oct 14, 2024

Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex

Oct 14, 2024
pulisher
Oct 09, 2024

Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex

Oct 09, 2024
pulisher
Oct 03, 2024

The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News

Oct 03, 2024
pulisher
Oct 01, 2024

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily

Oct 01, 2024
pulisher
Sep 30, 2024

Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com

Sep 30, 2024

Ascendis Pharma A S Adr Azioni (ASND) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.94
price down icon 3.89%
$72.00
price down icon 5.62%
$31.17
price up icon 0.13%
$18.80
price down icon 2.54%
$90.29
price down icon 0.85%
biotechnology ONC
$271.04
price down icon 0.42%
Capitalizzazione:     |  Volume (24 ore):